SDC1 and monoclonal gammopathy: This was done in order to evaluate the clinical utility of serum levels of CD138 in the differential diagnosis of monoclonal gammopathies as a parallel biomarker to be used in association with the FLC assay, especially in the light of therapy administration and monitoring relapsing effects.